DiscoverEvidence-Based GI: An ACG Publication and PodcastSubcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience with Potential for Improved Efficacy?
Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience with Potential for Improved Efficacy?

Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience with Potential for Improved Efficacy?

Update: 2024-11-19
Share

Description

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Elie S. Al Kazzi, MD, MPH discuss “Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY),” Gastroenterology. 2024;167:91 9–933.
Comments 
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience with Potential for Improved Efficacy?

Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience with Potential for Improved Efficacy?

2024-11-1919:04

On-Demand Vonoprazan for Non-Erosive Reflux Disease Symptoms: A New Option

On-Demand Vonoprazan for Non-Erosive Reflux Disease Symptoms: A New Option

2024-11-1914:50

Suboptimal Adherence to Guidelines When Recommending Timing of Repeat Colonoscopy

Suboptimal Adherence to Guidelines When Recommending Timing of Repeat Colonoscopy

2024-11-1915:40

Reintroducing Foods After Completing Restrictive Low FODMAP Diet

Reintroducing Foods After Completing Restrictive Low FODMAP Diet

2024-11-1914:56

Quality Indicators for Colonoscopy: New Targets… But Will They Be Measured?

Quality Indicators for Colonoscopy: New Targets… But Will They Be Measured?

2024-10-2225:00

Decreasing Cirrhosis Risk in MASLD: Don’t Drink Alcohol!

Decreasing Cirrhosis Risk in MASLD: Don’t Drink Alcohol!

2024-10-2210:33

A PPI a Day Keeps the GI Bleed Away in the ICU

A PPI a Day Keeps the GI Bleed Away in the ICU

2024-10-2212:33

A Laser Ruler to Hit the Mark on Polyp Size

A Laser Ruler to Hit the Mark on Polyp Size

2024-10-2214:22

ACG Guideline on Treatment of Helicobacter pylori: New Recommendations… Will Practice Change?

ACG Guideline on Treatment of Helicobacter pylori: New Recommendations… Will Practice Change?

2024-09-1720:08

Risankizumab is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC Treatment Paradigm

Risankizumab is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC Treatment Paradigm

2024-09-1716:38

Standardized Training for Endoscopic Mucosal Resection of Large Polyps: Does it Reduce Recurrence?

Standardized Training for Endoscopic Mucosal Resection of Large Polyps: Does it Reduce Recurrence?

2024-09-1717:00

Diagnostic Yield of Prolonged Wireless pH vs 24-hour pH-Impedance Monitoring for Evaluation of Chronic Laryngeal Symptoms

Diagnostic Yield of Prolonged Wireless pH vs 24-hour pH-Impedance Monitoring for Evaluation of Chronic Laryngeal Symptoms

2024-09-1720:12

Risankizumab is Superior to Ustekinumab for Induction and Maintenance of Crohn’s disease: The SEQUENCE Trial

Risankizumab is Superior to Ustekinumab for Induction and Maintenance of Crohn’s disease: The SEQUENCE Trial

2024-08-2021:59

Vonoprazan is Efficacious for Non-Erosive Reflux Disease (NERD): An Alternative for PPI-Resistant NERD Patients?

Vonoprazan is Efficacious for Non-Erosive Reflux Disease (NERD): An Alternative for PPI-Resistant NERD Patients?

2024-08-2012:28

ERCP with Extracorporeal Shock-Wave Lithotripsy for Chronic Pancreatitis: Is It A “Sham” for Improving Pain?

ERCP with Extracorporeal Shock-Wave Lithotripsy for Chronic Pancreatitis: Is It A “Sham” for Improving Pain?

2024-08-2011:25

ICYMI: ACG Clinical Guideline on Gastroparesis-Limited Evidence-Based Options

ICYMI: ACG Clinical Guideline on Gastroparesis-Limited Evidence-Based Options

2024-08-2020:21

Tirzepatide Produces NASH Resolution and Decreases Fibrosis: Results from the SYNERGY-NASH Trial

Tirzepatide Produces NASH Resolution and Decreases Fibrosis: Results from the SYNERGY-NASH Trial

2024-07-1610:07

Oral Vonoprazan for Prevention of High-Risk Peptic Ulcer Rebleeding: A Better Alternative than IV PPIs?

Oral Vonoprazan for Prevention of High-Risk Peptic Ulcer Rebleeding: A Better Alternative than IV PPIs?

2024-07-1614:52

Long-Term Efficacy and Safety of Ustekinumab for Ulcerative Colitis: 4-Year Data from the UNIFI Maintenance Study

Long-Term Efficacy and Safety of Ustekinumab for Ulcerative Colitis: 4-Year Data from the UNIFI Maintenance Study

2024-07-1613:59

Do Not Extend Interval Between CRC Screening Colonoscopies from 10 to 15 Years: Perils of Administrative Databases

Do Not Extend Interval Between CRC Screening Colonoscopies from 10 to 15 Years: Perils of Administrative Databases

2024-07-1613:09

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience with Potential for Improved Efficacy?

Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience with Potential for Improved Efficacy?

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Elie S. Al Kazzi, MD, MPH